Last edition
News about Global Pharma
Chugai Pharmaceutical to Acquire Renalys Pharma to Accelerate Access to Sparsentan Across Asia
Chugai Pharmaceutical has entered into a definitive stock purchase agreement to acquire Renalys Pharma, a company focused on advancing innovative therapies for chronic kidney disease across Asia.
Global Pharma | 24/10/2025 | By Dineshwori | 100
SystImmune and BMS Present Phase I Results of EGFR x HER3 Bispecific ADC at ESMO 2025
Iza-bren, a potentially first-in-class EGFR x HER3 bispecific Antibody-Drug Conjugate (ADC), is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive licence agreement in territories outside of Mainland China.
Global Pharma | 21/10/2025 | By Dineshwori
FDA Approves Oral Semaglutide by Novo Nordisk for CV Risk Reduction in Adults with Type 2 Diabetes
Rybelsus (Semaglutide) tablets, available in 7 mg and 14 mg doses, is the only FDA-approved oral GLP-1 therapy, and is now indicated to lower the risk of Major Adverse Cardiovascular Events (MACE)—including CV death, heart attack, or stroke—in adults with type 2 diabetes at high cardiovascular risk.
Global Pharma | 21/10/2025 | By Dineshwori
Aspire Pharma acquires Charlwood Pharma
Aspire Pharma, a UK-based specialty generics pharma business, has announced the acquisition of Charlwood Pharma Ltd — a privately-owned company specialising in the research and development of niche generic medicines. The deal marks the culmination of a successful multi-year collaboration between the two organisations.
Global Pharma | 21/10/2025 | By Dineshwori
Waters Corporation Unveils Xevo Charge Detection MS for Advanced Biomolecule Analysis
The new Xevo CDMS system by Waters Corporation enables measurement of large biomolecules to support Research and Development (R&D) in gene and protein-based therapies.
Global Pharma | 21/10/2025 | By Dineshwori
ManaMed Secures FDA Clearance for Next-Generation Tubeless Compression System, PlasmaFlow X
ManaMed, a US-based global leader in orthopedic mobility and post-operative rehabilitation equipment, has received FDA 510(k) clearance for PlasmaFlow X, its next-generation tubeless sequential compression system designed to redefine recovery and enhance patient comfort.
Global Pharma | 21/10/2025 | By Dineshwori
Korean biotech company SK Biopharmaceuticals and Brazil-based Eurofarma have established a joint venture, Mentis Care, in Canada to commercialise an AI-powered epilepsy management platform. The new company marks SK Biopharmaceuticals’ full-scale expansion into digital healthcare beyond its innovative drug development portfolio.
Global Pharma | 21/10/2025 | By Dineshwori | 104
Fabhalta from Novartis Meets Phase-III Goal in Slowing Kidney Decline in IgAN Patients
Fabhalta (iptacopan) from Novartis met its Phase III primary endpoint, slowing kidney function decline in IgA nephropathy (IgAN) patients. The first approved complement inhibitor for IgAN, Fabhalta builds on its 2024 U.S. accelerated approval, with data supporting a 2026 traditional FDA submission.
Global Pharma | 17/10/2025 | By Dineshwori
NAYA Therapeutics, a US-based clinical-stage biopharmaceutical company developing next-generation cancer therapies, has entered into a research and manufacturing partnership with China’s Alpha Nuclide, a radiopharmaceutical solutions company leading global efforts in Astatine-211 (211At) supply and CDMO services.
Global Pharma | 17/10/2025 | By Dineshwori
Graph Secures USD 3 Million Seed Funding from Bessemer for AI-Driven Drug Safety
California-based Graph AI has announced its USD 3 Million Seed round, led by Bessemer Venture Partners. The investment will enable Graph to accelerate product innovation, expand its engineering team, and drive global market adoption.
Global Pharma | 17/10/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy